Leflunomide Tillomed

Leflunomide, the active ingredient in Leflunomide Tillomed, is an immunomodulator (DMARD) presented as an oral dosage form for systemic use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients. GNH USA supplies Leflunomide Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is used within the disease‑modifying antirheumatic drug class to control inflammatory joint diseases. - Rheumatoid arthritis: reduces disease activity, slows joint damage and improves functional status. - Psoriatic arthritis: alleviates joint inflammation, skin lesions and prevents structural progression.

Leflunomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhoea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Alopecia: reversible hair thinning. - Rash: non‑specific skin eruptions. - Elevated liver enzymes: transient increases in ALT/AST. - Hypertension: modest rise in blood pressure.

Serious or Rare Side Effects: - Severe liver injury: rare but may lead to hepatic failure. - Stevens‑Johnson syndrome: life‑threatening skin reaction. - Bone‑marrow suppression: pancytopenia or aplastic anaemia. - Interstitial lung disease: pulmonary inflammation. - Severe infections: opportunistic bacterial or viral infections. - Teratogenicity: fetal malformations when exposure occurs in pregnancy.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on risk mitigation. - Liver monitoring: obtain baseline and periodic ALT/AST levels. - Blood pressure: monitor regularly, especially in hypertensive patients. - Pregnancy avoidance: contraindicated in pregnancy; effective contraception required. - Infection risk: screen for active infections and avoid live vaccines. - Hematology: periodic complete blood counts to detect cytopenias. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Leflunomide can alter the pharmacokinetics or pharmacodynamics of several co‑administered drugs.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Carbamazepine: induces metabolism, reducing leflunomide exposure. - Azathioprine: additive bone‑marrow suppression. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Statins: potential for myopathy. - Methotrexate: combined hepatotoxicity. - NSAIDs: may exacerbate liver enzyme elevations.